Pittenger & Anderson Inc’s Inovio Pharmaceuticals INO Stock Holding History

Pittenger & Anderson Inc’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$85	Hold	77	–	–	﹤0.01%	506
2026 Q1	$134	Hold	77	–	–	﹤0.01%	518
2025 Q4	$134	Hold	77	–	–	﹤0.01%	508
2025 Q3	$181	Hold	77	–	–	﹤0.01%	453
2025 Q2	$157	Hold	77	–	–	﹤0.01%	416
2025 Q1	$126	Hold	77	–	–	﹤0.01%	422
2024 Q4	$141	Hold	77	–	–	﹤0.01%	430
2024 Q3	$446	Hold	77	–	–	﹤0.01%	443
2024 Q2	$623	Hold	77	–	–	﹤0.01%	427
2024 Q1	$1.07K	Buy	+77	New	+$665	﹤0.01%	407
2020 Q1	–	Sell	-250	Closed	-$10K	–	368
2019 Q4	$10K	Hold	250	–	–	﹤0.01%	321
2019 Q3	$6K	Hold	250	–	–	﹤0.01%	332
2019 Q2	$9K	Hold	250	–	–	﹤0.01%	327
2019 Q1	$11K	Hold	250	–	–	﹤0.01%	323
2018 Q4	$12K	Hold	250	–	–	﹤0.01%	310
2018 Q3	$17K	Hold	250	–	–	﹤0.01%	303
2018 Q2	$12K	Hold	250	–	–	﹤0.01%	326
2018 Q1	$14K	Hold	250	–	–	﹤0.01%	322
2017 Q4	$12K	Hold	250	–	–	﹤0.01%	346
2017 Q3	$19K	Hold	250	–	–	﹤0.01%	309
2017 Q2	$24K	Buy	+250	New	+$21.4K	﹤0.01%	306
2017 Q1	–	Sell	-250	Closed	-$21K	–	350
2016 Q4	$21K	Buy	+250	New	+$22.6K	﹤0.01%	312

Other funds holding INO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BCM

Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Pittenger & Anderson Inc's INO Position: Q2 2026 in Review

Pittenger & Anderson Inc held its Inovio Pharmaceuticals (INO) position steady in Q2 2026 at 77 shares worth $85. The position accounts for ﹤0.01% of the portfolio, ranked #506.

Pittenger & Anderson Inc first reported a position in INO in Q4 2016 and has held it in 22 quarters since. The position peaked at $24K in Q2 2017. 103 funds tracked by Wall St. Rank hold INO as of Q2 2026.

Pittenger & Anderson Inc held 77 shares of Inovio Pharmaceuticals worth $85 as of Q2 2026.
Pittenger & Anderson Inc left its Inovio Pharmaceuticals share count unchanged in Q2 2026.
Inovio Pharmaceuticals made up ﹤0.01% of Pittenger & Anderson Inc's portfolio in Q2 2026, its #506 holding.
Pittenger & Anderson Inc first reported a position in Inovio Pharmaceuticals in Q4 2016 and has held it in 22 quarters since.
Pittenger & Anderson Inc's Inovio Pharmaceuticals position peaked at $24K in Q2 2017.
103 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q2 2026.

Based on Pittenger & Anderson Inc's 13F filing for Q2 2026, filed 27 Jul 2026.